文献速递食管与纵隔外科

术前活检与手术切除局限性胸腺瘤总生存无关

Preoperative Biopsy Is Not Associated With Overall Survival in Patients With Surgically Resected Localized Thymoma.
PubMed 文献 · Eur J Cardiothorac Surg · 2025-01-01

该研究基于美国国家癌症数据库2004-2015年1056例接受 upfront R0 胸腺切除术的局限性胸腺上皮肿瘤成人患者,评估术前活检与总生存的关系。结果显示术前经皮活检使用率从2006年18%增至2015年33%(P < .001),活检组与未活检组10年OS无差异[75% (95% CI 69%-82%) vs 76% (95% CI 73%-80%),P = .8],校正后OS仍相似[AHR 0.97 (95% CI 0.72-1.29),P = .9]。

要点

  • 术前活检未与局限性胸腺上皮肿瘤患者更差的总生存相关
  • 术前经皮活检使用率2006-2015年从18%升至33%
  • 活检组肿瘤更大、开放手术和区域淋巴结清扫比例更高、住院更长

核心结论

  • 在局限性胸腺上皮肿瘤接受 upfront R0 胸腺切除术的患者中,术前活检与更差的总生存无关。

研究设计与样本

  • 回顾性队列研究,查询美国国家癌症数据库2004-2015年接受 upfront R0 胸腺切除术的局限性胸腺上皮肿瘤成人患者,共1056例。

主要发现

  • 术前经皮活检使用率2006-2015年从18%增至33%(P < .001)。
  • 活检组肿瘤中位大小6.6 cm vs 5.0 cm,开放手术72% (150) vs 62% (331),区域淋巴结清扫44% (118) vs 33% (250),住院中位4天 vs 3天。
  • 活检组与未活检组10年OS无差异[75% (95% CI 69%-82%) vs 76% (95% CI 73%-80%),P = .8]。
  • 校正年龄、性别、主要支付方、组织学和肿瘤大小后,OS仍相似[AHR 0.97 (95% CI 0.72-1.29),P = .9]。

临床怎么用

  • 对于局限性胸腺上皮肿瘤拟行 upfront R0 胸腺切除术的患者,术前活检未显示与更差总生存相关。
  • 临床决策时仍需权衡活检的潜在风险与获益,尤其复发风险尚需进一步研究。

局限性

  • 需更多研究进一步探讨活检是否增加复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Society guidelines discourage biopsy of thymic epithelial tumours (TETs) due to the perceived risk of local seeding or pleural dissemination. However, few studies have evaluated this concern, and the true risk of preoperative biopsy remains unknown. METHODS: We queried the United States' National Cancer Database for adults with localized TETs who underwent upfront R0 thymectomy 2004-2015. Use of preoperative biopsy over time was assessed with the Cochran-Armitage test. Postoperative outcomes were compared with chi-square and Wilcoxon rank sum tests. Overall survival (OS) was analysed with Kaplan-Meier and Cox proportional hazard methods. RESULTS: We identified 1056 patients. The median age was 61 years; 47% (492) were male. Use of preoperative percutaneous biopsy increased 2006-2015 from 18% to 33% (P < .001). Patients who underwent biopsy had larger tumours [median 6.6 vs 5.0 cm], more open operations [72% (150) vs 62% (331)] and regional lymphadenectomies [44% (118) vs 33% (250)], and a longer length of hospitalization (median 4 vs 3 days). Thirty-day mortality was similar between the groups. There was no difference in 10-year OS between the biopsy and no-biopsy groups [75% (95% CI 69%-82%) vs 76% (95% CI 73%-80%), P = .8]. After adjusting for age, sex, primary payor, histology, and tumour size, OS was similar between the biopsy and no-biopsy groups [AHR 0.97 (95% CI 0.72-1.29), P = .9]. CONCLUSIONS: In this analysis of patients with localized TETs undergoing upfront R0 thymectomy, preoperative biopsy is not associated with worse OS. More study is needed to further explore whether biopsy increases risk of recurrence.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Powell C, Day C, Wigle D, et al. Preoperative Biopsy Is Not Associated With Overall Survival in Patients With Surgically Resected Localized Thymoma. Eur J Cardiothorac Surg. 2025. PMID: 41330695. doi:10.1093/ejcts/ezaf431

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。